摘要
目的探讨乳腺癌组织中c-erbB-2和组织蛋白酶D（cath—D）的表达水平与临床病理及预后的关系。方法选取128例乳腺癌患者，采用免疫组化法检测c—erbB-2和cath—D蛋白的表达水平。并与患者的临床病理指标和预后做关联分析。结果c-erbB-2阳性率为36．5％，cath-D阳性表达率为40．9％。cath—D的表达水平与患者肿块直径大小显著相关，肿瘤直径〉5cm者cath—D的阳性率显著高于〈2cm者（x^2=21．0，P〈0．0001）；cath-D阴性的68例中，24例（35．29％）有淋巴结转移，cath-D阳性者淋巴结转移率（63．83％）明显高于cath-D阴性者（P〈O．0001）。c—erbB-2表达比不表达患者预后差（P=0．01）。结论c-erbB-2阳性表达和cath-D阳性表达者，恶性程度高，易转移、预后差。
Objective To investigate the expression of c-erbB-2 and cathepsin D （cath-D） in primary breast carcinoma, and to analyze its relationship to the patients＂ clinicopathological status and its prognostic significance. Methods The immnohistochemical test were used to detect the expression of c-erbB-2 and cath-D in 128 patients with primary breast carcinoma. All data were statistically analyzed. Results The positive expression rate of c-erbB-2 and cath-D was 36.5 % and 40.9 %, relatively. Cath-D was correlated with tumor size （X^2=21.0, P 〈0.0001） and lymph node status （35.29 % vs 63.83 %, P 〈0.0001）. The Kaplan-Meier curve and log rank test indicated that the positive c-erbB-2 expression was a significant prognostic factor for patients disease free survival （P〈0.01）. Conclusion c-erbB-2 and cath-D show a clinicopathological invasive characteristic. They are prognostic factors for patients with primary breast carcinoma, and also can be prognostic indicator for patients.
出处
《肿瘤研究与临床》
CAS
2011年第2期103-105,共3页
Cancer Research and Clinic
